BIOMAT Database Logo BIOMAT Database Logo

Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. 1996

R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892, USA.

Tumor necrosis factor-alpha (TNF-alpha), a proinflammatory cytokine known to stimulate human immunodeficiency virus type 1 (HIV-1) replication, has been implicated in the pathogenesis of HIV-1 infection. Inhibition of TNF-alpha by a chimeric humanized monoclonal antibody, cA2, was investigated in 6 HIV-1-infected patients with CD4 cell counts < 200/mm3. Two consecutive infusions of 10 mg/kg 14 days apart were well tolerated, and a prolonged serum half-life for cA2 (mean, 257 +/- 70 h) was demonstrated. Serum immunoreactive TNF-alpha concentrations fell from a mean prestudy value of 6.4 pg/mL (range, 4.2-7.9) to 1.1 pg/mL (range, 0.5-2.2) 24 h after the first infusion and returned to baseline within 7-14 days. A similar response was seen after the second infusion. No consistent changes in CD4 cell counts or plasma HIV RNA levels were observed over 42 days. Future studies evaluating the therapeutic utility of long-term TNF-alpha suppression using anti-TNF-alpha antibodies are feasible and warranted.

UI MeSH Term Description Entries
D008297 Male Males
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor alpha.
April 1989, AIDS research and human retroviruses,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus.
September 1989, The Journal of clinical investigation,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Salmonella typhimurium activates human immunodeficiency virus type 1 in chronically infected promonocytic cells by inducing tumor necrosis factor-alpha production.
May 1994, Biochemical and biophysical research communications,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Elevated levels of circulating tumor necrosis factor alpha in human immunodeficiency virus type 1-infected Africans living in Sweden.
January 1995, Clinical and diagnostic laboratory immunology,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1.
April 1992, Journal of virology,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity.
June 2007, Neurobiology of disease,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha in patients with human immunodeficiency virus (HIV) type 1 infection.
January 1993, Microbiology and immunology,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages.
January 1991, The Journal of infectious diseases,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Human immunodeficiency virus type 1 envelope glycoprotein gp120 induces tumor necrosis factor-alpha in astrocytes.
January 1999, Journal of neuro-AIDS,
R E Walker, and K M Spooner, and G Kelly, and R V McCloskey, and J N Woody, and J Falloon, and M Baseler, and S C Piscitelli, and R T Davey, and M A Polis, and J A Kovacs, and H Masur, and H C Lane
Elevated levels of tumor necrosis factor alpha (TNF-alpha) in human immunodeficiency virus type 1-transgenic mice: prevention of death by antibody to TNF-alpha.
November 2002, Journal of virology,
Copied contents to your clipboard!